Prognosis
Antibody Therapies Take the Spotlight as Covid-19 ‘Plan B’
- Lilly, Regeneron in the lead for a new kind of treatment
- Regeneron shares at a record after Warp Speed backing
This article is for subscribers only.
An experimental antibody therapy to combat Covid-19 from Regeneron Pharmaceuticals Inc. got a shot of confidence from the U.S. government on Tuesday with a $450 million contract to start amping up production.
With Regeneron and Eli Lilly & Co. expected to have results in the current quarter, the latest funding may signal a new plan of attack for President Donald Trump.